Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1289)	3/31/2006 12:35:56 PM
From: JOEBT1	Respond to of 2240

Erik I believe the new trial strategy leap frogs Pfizer and greatly enhances MEDX chances in bringing MDX-010 to market first in its most effective form/dose. The monotherapy trial with 10mg doses can take all patients (50% of patients in the current 3mg/vaccine trial are lost because they don't meet requirements). The enrollment will be very quick, drawing patients from the current Medx and Pfizer trials. I would guess the trial will be fully enrolled well before the end of the year setting up the FDA filing in 2007. I feel much more confident that Medx and BMY will win the race to bring MDX-010 to the market first in its most effective form. What's your view? Joe